In particular, SCNEC is generally characterized by low PD-L1 expression, low tumor mutational burden (TMB), and microsatellite stability (MSS), classifying it as an immunologically “cold” tumor with limited responsiveness to ICIs (83–85). The gene discussed is CD274; the disease is neoplasm.